Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Cancer ; 135(4): 830-42, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-24415578

ABSTRACT

Immunotherapy of usual vulvar intraepithelial neoplasia (uVIN) is promising; however, many patients still fail to show clinical responses, which could be explained by an immune escape through alterations in human leukocyte antigen (HLA) expression. Therefore, we analyzed a cohort of patients with a primary (n = 43) and subsequent recurrent uVIN lesion (n = 20), vaccine-treated uVIN patients (n = 12), patients with human papillomavirus (HPV)-induced vulvar carcinoma (n = 21) and healthy controls (n = 26) for the expression of classical HLA-class I/II and nonclassical HLA-E/-G and MHC class I chain-related molecule A (MICA). HLA-class I was downregulated in 70% of uVIN patients, including patients with a clinical response to immunotherapy. Downregulation of HLA-class I is probably reversible, as only 15% of the uVIN cases displayed loss of heterozygosity (LOH) and HLA-class I could be upregulated in uVIN keratinocyte cultures by interferon γ. HLA-class I downregulation is more frequently associated with LOH in vulvar carcinomas (25-55.5%). HLA-class II was found to be focally expressed in 65% of uVIN patients. Of the nonclassical molecules, MICA was downregulated in 80% of uVIN whereas HLA-E and -G were expressed in a minority of cases. Their expression was more prominent in vulvar carcinoma. No differences were found between the alterations observed in paired primary and recurrent uVIN. Importantly, downregulation of HLA-B/C in primary uVIN lesions was associated with the development of recurrences and progression to cancer. We conclude that downregulation of HLA is frequently observed in premalignant HPV-induced lesions, including clinical responders to immunotherapy, and is associated with worse clinical outcome. However, in the majority of cases downregulation may still be reversible.


Subject(s)
Carcinoma/immunology , HLA Antigens/metabolism , Immunotherapy/methods , Papillomavirus Infections/immunology , Vulvar Neoplasms/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma/therapy , Carcinoma/virology , Case-Control Studies , Cohort Studies , Down-Regulation , Female , Gene Expression Regulation , Gene Expression Regulation, Neoplastic , Genotype , Humans , Interferon-gamma/metabolism , Keratinocytes/cytology , Keratinocytes/drug effects , Keratinocytes/virology , Loss of Heterozygosity , Middle Aged , Papillomavirus Infections/therapy , Recurrence , Vulvar Neoplasms/therapy , Vulvar Neoplasms/virology
2.
Br J Cancer ; 109(8): 2259-65, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-24064972

ABSTRACT

BACKGROUND: Vulvar cancer is the fourth most common gynaecological malignancy, with an annual incidence of 2 out of 100,000 women. Although most cases of early stage vulvar cancer have a good prognosis, recurrence and rapid tumour progression can occur. We investigated the prevalence of spindle cell morphology in vulvar cancer and its association with survival. METHODS: This retrospective cohort study included 108 patients with primary vulvar squamous cell carcinoma who were treated at the Leiden University Medical Center during 2000-2009. Paraffin-embedded tissue was examined for the presence of spindle cell morphology. Survival and histology data were compared between cases with spindle and without spindle cell morphology. RESULTS: Twenty-two (20%) tumours showed spindle cells infiltrating the stromal tissue. All spindle cell tumours were human papillomavirus (HPV) negative. Spindle cell morphology was strongly associated with poor prognosis and with a high risk of lymph node involvement at the time of diagnosis (relative risk 2.26 (95% CI 1.47-3.47)). Five-year disease-specific survival was lower in patients with vs without spindle cell morphology (45.2% vs 79.7%, respectively; P=0.00057). CONCLUSION: Vulvar spindle cell morphology occurs frequently and seems to develop through the non-HPV pathway. It is associated with a worse prognosis than conventional vulvar squamous cell carcinoma.


Subject(s)
Carcinoma, Squamous Cell/pathology , Vulvar Neoplasms/pathology , Aged , Cohort Studies , Female , Humans , Multivariate Analysis , Neoplasm Staging , Prognosis , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL